TELA Bio, Inc.: insider trades · United States · SEC (Form 4)

About TELA Bio, Inc.

TELA Bio, Inc. is a U.S.-based medical technology company listed on the NASDAQ market in the United States (United States). Founded in 2012 and headquartered in Malvern, Pennsylvania, the company focuses on soft-tissue reconstruction and hernia repair solutions designed to preserve and restore the patient’s anatomy while reducing long-term exposure to permanent synthetic materials. Its headquarters and R&D activities are centered in Malvern, in the greater Philadelphia area, which supports a commercial-stage operating model with a strong clinical and product-development orientation. TELA Bio’s core franchise is its OviTex portfolio, a family of reinforced tissue matrices used primarily in hernia repair and abdominal wall reconstruction. The portfolio includes products for open, laparoscopic, and robotic-assisted procedures, as well as versions tailored to plastic and reconstructive surgery. This product set is the company’s key differentiator: it targets surgeons who want an alternative to conventional permanent synthetic mesh and to some biologic matrices, while still seeking reinforcement strength and favorable handling characteristics in the operating room. The company’s strategy is built around the idea that surgeons increasingly value solutions that align with natural healing and tissue remodeling. From a competitive standpoint, TELA Bio operates in a large and clinically important market. Hernia repair is one of the most common surgical categories in the U.S., and the company’s SEC filings emphasize a meaningful addressable opportunity for OviTex across ventral, inguinal, and complex abdominal wall indications. The company’s commercial footprint remains primarily U.S.-driven, with a direct sales focus, but it has also been building an international presence, particularly in Europe. That international expansion is still early relative to the U.S. business, yet it has become a more visible part of the growth story. Recent corporate developments suggest an execution-focused phase for the business. In May 2026, TELA Bio reported first-quarter 2026 revenue of $19.1 million, up 3% year over year, and highlighted 41% year-over-year growth in European revenue. The company also announced the U.S. commercial launch of OviTex LTR, described as a fully resorbable, tissue-based hernia repair solution. In addition, management disclosed a strategic board refreshment aimed at accelerating growth and driving the company toward profitability. For investors, TELA Bio remains a niche but differentiated medtech name: a small-cap commercial-stage platform with a focused product line, a clear surgical use case, and growing evidence of geographic diversification beyond its core U.S. market.